Navigation Links
Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change
Date:12/10/2008

GARDNER, Mass., Dec. 10 /PRNewswire-FirstCall/ -- Precision Optics Corporation, Inc., (OTC Bulletin Board: POCI) (the "Company"), announced today a 1-for-25 reverse split of the company's common stock. Stockholders approved the reverse split at the Company's annual meeting on November 25, 2008. The Board of Directors has determined that the reverse split is in the best interests of both Precision Optics Corporation and its stockholders, providing the benefits from a capital structure more appropriate to the Company and its future potential. We believe that the change will open the door to a more diversified and serious investment interest, and will position the company for future growth.

The split will be effective when the market opens on December 11, 2008. Precision Optics Corporation, Inc.'s ticker symbol will change to PEYE.OB. The Company has amended its restated Articles of Organization, as amended, to effect the reverse split, which will affect all outstanding shares of Precision Optics Corporation common stock, including those shares underlying outstanding stock options, warrants and other convertible securities immediately prior to the effective date.

This release contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the reasons described in the Company's annual report on Form 10-K and other reports it files with the Securities and Exchange Commission. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made. The Company does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as required by law.

About Precision Optics

Precision Optics Corporation, Inc., a developer and manufacturer of advanced optical instruments since 1982, designs and produces high-quality medical instruments, micro-optics with characteristic dimensions less than 1 mm, and other advanced optical systems. The Company's medical instrumentation line includes laparoscopes, arthroscopes and endocouplers and a line of world-class 3-D endoscopes for use in minimally invasive surgical procedures. The Company continues to advance products through technical innovation, including development of: the next generation (patent pending) of 3-D endoscopes; the extension of Lenslock(TM) technology (patent pending) to its entire line of endoscopes; instrumentation utilizing the Company's micro-precision(TM) lens technology (patent pending) for optical components, assemblies and endoscopes under 1 mm. Precision Optics Corporation is registered to ISO 9001:2000, ISO 13485:2003, and CMDCAS Quality Standards, and complies with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE Marking of its medical products. The Company's Internet Website is http://www.poci.com.


'/>"/>
SOURCE Precision Optics Corporation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Optics Corporation Announces Fourth Quarter and Year End Results With Highest Revenues in Six Years
2. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
3. New Generation Xcelodose(R)S Precision Drug Powder Micro-filling System Offers 50% Increased Throughput
4. Precision Optics Corporation Announces First Quarter Results and Receipt of Significant New Order
5. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15%
6. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
7. Precision Therapeutics Adds 8 Million Covered Lives Under Contract
8. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
9. Precision Therapeutics President and CEO Sean McDonald Named Ernst & Young Entrepreneur of the Year(R) 2008 Regional Award Winner
10. Vapotherm(R) Precision Flow(TM) Receives FDA 510(k) Clearance
11. Precision Therapeutics Secures $43 Million in Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and ... leader SAS will provide researchers worldwide with data management and analytics tools to explore ... , The DCRI and SAS share the goal of greater transparency and openness in ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... Dallas, Texas (PRWEB) , ... May 04, 2016 , ... ... cancer awareness in people across the United States. Dermatologist Dr. Ellen Turner is encouraging ... heed dermatology experts’ advice and focus on skin safety and health now and in ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Dr. ... offering wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental ... not always problematic, they often are improperly erupted, resulting in risks of complications. By ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals ... cellular and metabolic health. This synergistic combination of omega-3 fatty acids and potent ... 150 mg of reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
Breaking Medicine Technology: